by
John R. Fischer, Senior Reporter | April 11, 2023
Micro C (Photo courtesy of OXOS Medical)
OXOS Medical raised $23 million in Series A funding toward its “radiology department in a box” solution, Micro C, a handheld miniature C-arm that captures both static and live images for diagnostic and surgical radiography in point-of-care settings.
Unlike traditional C-arms, Micro C can be easily moved within operating rooms, and deployed outside hospitals and ambulatory surgery sites in primary care clinics, emergency departments, urgent care centers, outpatient clinics, mobile imaging services and cadaver labs.
“This fundraise was all about setting OXOS up for scale, specifically expanding access to our safe, powerful, and simple X-ray technology across the entire healthcare value chain. Across hospital settings and into mobile, remote, and home healthcare — essentially, anywhere where X-rays are needed,” OXOS Medical told HCB News.
The Series A round, financed by investment firms Parkway Venture Capital and Intel Capital, brings total funding for Micro C to $45 million. Parkway Venture Capital co-founder and managing partner Gregg Hill and Intel Capital Investment director Eric King will join the OXOS board of directors to continue accelerating growth.
Capable of performing both digital and dynamic digital radiography, Micro C consists of a handheld emitter, high sensitivity X-ray detector, and a patented positioning system. It combines advanced image processing, computer vision and X-ray tube architecture to reduce radiation and increase safety.
The solution directly connects clinicians to the HIPAA-compliant OXOS Cloud Platform to review radiographic studies, from any device, with the platform integrating within existing radiology infrastructure and using OXOS’ nationwide teleradiology services to interpret scans.
Reimbursement is the same as with existing X-ray machines, with special moving X-ray CPT codes available to Micro C users for additional capabilities. The solution was also
cleared in 2021 for use on pediatric patients.
The company is preparing to launch its next device, with FDA approval expected sometime this summer.
